
Prostate cancer (PCa) is the most frequent cancer found in males worldwide, and its mortality rate is increasing every year. To discover key molecular changes in PCa development and metastasis, we analyzed microarray data of localized PCa, metastatic PCa and normal prostate tissue samples from clinical specimens.
Gene expression profiling datasets of PCa were analyzed online. The DAVID was used to perform GO functional and KEGG pathway enrichment analyses. CytoHubba in Cytoscape software was applied to identify hub genes. Survival data were downloaded from GEPIA. Gene expression data were obtained from ONCOMINE and UALCAN.
We obtained 4 sets of differentially expressed genes (DEGs), DEGs 1: a comparison of the gene expression between 4 normal prostate and 5 localized PCa samples in GSE27616; DEGs 2: a comparison of the gene expression between 6 normal prostate and 7 localized PCa samples in GSE3325; DEGs 3: a comparison of the gene expression between 5 localized PCa and 4 metastatic PCa samples in GSE27616; DEGs 4: a comparison of the gene expression between 7 localized PCa and 6 metastatic PCa samples in GSE3325. A comparison of these 4 sets of genes revealed 51 overlapped genes. GO function analysis revealed enrichment of the 51 DEGs in functions related to the proteinaceous extracellular matrix and centrosome, protein homodimerization activity and chromatin binding were the main functions of these genes, which participated in regulating cell division, mitotic nuclear division, proteinaceous extracellular matrix, cell adhesion and apoptotic process. KEGG pathway analysis indicated that these identified DEGs were mainly enriched in progesterone-mediated oocyte maturation, oocyte meiosis and cell cycle. We defined the 16 genes with the highest degree of connectivity as the hub genes in the 51 overlapped DEGs. Cox regression revealed TOP2A, CCNB2, BUB1, CDK1 and EZH2 were related to Disease-free survival (DFS). The expression levels of the 5 genes were 2.232-, 1.786-, 2.303-, 1.699-, and 1.986-fold higher in PCa than the levels in normal tissues, respectively (P < 0.05). We obtained 20 hub genes from DEGs by the comparison of normal prostate tissue vs. localized cancer tissue. Among them, KIF20A, CDKN3, PBK and CDCA2, were expressed higher in PCa than in normal tissues, and were associated with the DFS of PCa patients. Meanwhile, we obtained 20 hub genes from DEGs by the comparison of localized cancer tissue vs. metastatic cancer tissue. Cox regression revealed PLK1, CCNA2 and CDC20, were associated with both the DFS and overall survival of PCa patients.
The results suggested that the functions of KIF20A, CDKN3, PBK and CDCA2 may contribute to PCa development and the functions of PLK1, CCNA2 and CDC20 may contribute to PCa metastasis. Meanwhile, the functions of TOP2A, CCNB2, BUB1, CDK1 and EZH2 may contribute to both PCa development and metastasis.
Citation: Peng Gu, Dongrong Yang, Jin Zhu, Minhao Zhang, Xiaoliang He. Bioinformatics analysis identified hub genes in prostate cancer tumorigenesis and metastasis[J]. Mathematical Biosciences and Engineering, 2021, 18(4): 3180-3196. doi: 10.3934/mbe.2021158
[1] | Zhenlei Yang, Jie Wang, Ruixi Zhu . Identification of driver genes with aberrantly alternative splicing events in pediatric patients with retinoblastoma. Mathematical Biosciences and Engineering, 2021, 18(1): 328-338. doi: 10.3934/mbe.2021017 |
[2] | Jie Wang, Md. Nazim Uddin, Rehana Akter, Yun Wu . Contribution of endothelial cell-derived transcriptomes to the colon cancer based on bioinformatics analysis. Mathematical Biosciences and Engineering, 2021, 18(6): 7280-7300. doi: 10.3934/mbe.2021360 |
[3] | Ahmed Hammad, Mohamed Elshaer, Xiuwen Tang . Identification of potential biomarkers with colorectal cancer based on bioinformatics analysis and machine learning. Mathematical Biosciences and Engineering, 2021, 18(6): 8997-9015. doi: 10.3934/mbe.2021443 |
[4] | Miao Zhu, Tao Yan, Shijie Zhu, Fan Weng, Kai Zhu, Chunsheng Wang, Changfa Guo . Identification and verification of FN1, P4HA1 and CREBBP as potential biomarkers in human atrial fibrillation. Mathematical Biosciences and Engineering, 2023, 20(4): 6947-6965. doi: 10.3934/mbe.2023300 |
[5] | Hao Shen, Xiao-Dong Weng, Du Yang, Lei Wang, Xiu-Heng Liu . Long noncoding RNA MIR22HG is down-regulated in prostate cancer. Mathematical Biosciences and Engineering, 2020, 17(2): 1776-1786. doi: 10.3934/mbe.2020093 |
[6] | Fang Niu, Zongwei Liu, Peidong Liu, Hongrui Pan, Jiaxue Bi, Peng Li, Guangze Luo, Yonghui Chen, Xiaoxing Zhang, Xiangchen Dai . Identification of novel genetic biomarkers and treatment targets for arteriosclerosis-related abdominal aortic aneurysm using bioinformatic tools. Mathematical Biosciences and Engineering, 2021, 18(6): 9761-9774. doi: 10.3934/mbe.2021478 |
[7] | Yang Yu, Zhe Wang, Dai hai Mo, Zhen Wang, Gang Li . Transcriptome profiling reveals liver metastasis-associated genes in pancreatic ductal adenocarcinoma. Mathematical Biosciences and Engineering, 2021, 18(2): 1708-1721. doi: 10.3934/mbe.2021088 |
[8] | Tingting Chen, Wei Hua, Bing Xu, Hui Chen, Minhao Xie, Xinchen Sun, Xiaolin Ge . Robust rank aggregation and cibersort algorithm applied to the identification of key genes in head and neck squamous cell cancer. Mathematical Biosciences and Engineering, 2021, 18(4): 4491-4507. doi: 10.3934/mbe.2021228 |
[9] | Jiaping Wang . Prognostic score model-based signature genes for predicting the prognosis of metastatic skin cutaneous melanoma. Mathematical Biosciences and Engineering, 2021, 18(5): 5125-5145. doi: 10.3934/mbe.2021261 |
[10] | Jihong Yang, Hao Xu, Congshu Li, Zhenhao Li, Zhe Hu . An explorative study for leveraging transcriptomic data of embryonic stem cells in mining cancer stemness genes, regulators, and networks. Mathematical Biosciences and Engineering, 2022, 19(12): 13949-13966. doi: 10.3934/mbe.2022650 |
Prostate cancer (PCa) is the most frequent cancer found in males worldwide, and its mortality rate is increasing every year. To discover key molecular changes in PCa development and metastasis, we analyzed microarray data of localized PCa, metastatic PCa and normal prostate tissue samples from clinical specimens.
Gene expression profiling datasets of PCa were analyzed online. The DAVID was used to perform GO functional and KEGG pathway enrichment analyses. CytoHubba in Cytoscape software was applied to identify hub genes. Survival data were downloaded from GEPIA. Gene expression data were obtained from ONCOMINE and UALCAN.
We obtained 4 sets of differentially expressed genes (DEGs), DEGs 1: a comparison of the gene expression between 4 normal prostate and 5 localized PCa samples in GSE27616; DEGs 2: a comparison of the gene expression between 6 normal prostate and 7 localized PCa samples in GSE3325; DEGs 3: a comparison of the gene expression between 5 localized PCa and 4 metastatic PCa samples in GSE27616; DEGs 4: a comparison of the gene expression between 7 localized PCa and 6 metastatic PCa samples in GSE3325. A comparison of these 4 sets of genes revealed 51 overlapped genes. GO function analysis revealed enrichment of the 51 DEGs in functions related to the proteinaceous extracellular matrix and centrosome, protein homodimerization activity and chromatin binding were the main functions of these genes, which participated in regulating cell division, mitotic nuclear division, proteinaceous extracellular matrix, cell adhesion and apoptotic process. KEGG pathway analysis indicated that these identified DEGs were mainly enriched in progesterone-mediated oocyte maturation, oocyte meiosis and cell cycle. We defined the 16 genes with the highest degree of connectivity as the hub genes in the 51 overlapped DEGs. Cox regression revealed TOP2A, CCNB2, BUB1, CDK1 and EZH2 were related to Disease-free survival (DFS). The expression levels of the 5 genes were 2.232-, 1.786-, 2.303-, 1.699-, and 1.986-fold higher in PCa than the levels in normal tissues, respectively (P < 0.05). We obtained 20 hub genes from DEGs by the comparison of normal prostate tissue vs. localized cancer tissue. Among them, KIF20A, CDKN3, PBK and CDCA2, were expressed higher in PCa than in normal tissues, and were associated with the DFS of PCa patients. Meanwhile, we obtained 20 hub genes from DEGs by the comparison of localized cancer tissue vs. metastatic cancer tissue. Cox regression revealed PLK1, CCNA2 and CDC20, were associated with both the DFS and overall survival of PCa patients.
The results suggested that the functions of KIF20A, CDKN3, PBK and CDCA2 may contribute to PCa development and the functions of PLK1, CCNA2 and CDC20 may contribute to PCa metastasis. Meanwhile, the functions of TOP2A, CCNB2, BUB1, CDK1 and EZH2 may contribute to both PCa development and metastasis.
Prostate cancer (PCa) is the second most frequent cancer found in men worldwide (after lung cancer), with an estimate of 248, 530 new cases and 34, 130 deaths in the United States in 2021. And PCa is the second leading cause of cancer death in American men and survival rates are low for prostate cancers that advance to metastatic castrationresistant prostate cancer (mCRPC). Despite recent advances and a range of treatment options for mCRPC, outcomes are varied and clinicians are not able to predict response to the available therapies ADDIN EN.CITE.DATA [2]. Therefore, the need to more accurately identify lethal PCa, in an effort to personalize medicine for those in need, has led to a large-scale push for biomarker development in the field.
Many efforts based on microarray have been done in order to select the key genes associated with PCa. Due to microarray technology, it is easier to analyze the genetic alterations underlying PCa development and progression. In addition, through bioinformatics tools it is possible to identify new biomarkers and to construct networks that could be valuable for the management of PCa patients ADDIN EN.CITE.DATA [3]. However, to date, it has been difficult to identify key genes related and distinguished to PCa development and metastasis from microarray data. To discover key molecules active in PCa development and metastasis, we analyzed PCa data from microarray data. Our results suggested KIF20A, CDKN3, PBK and CDCA2 may contribute to PCa development, PLK1, CCNA2 and CDC20 may contribute to PCa metastasis, TOP2A, CCNB2, BUB1, CDK1 and EZH2 may contribute to PCa development and metastasis.
The gene expression profiling datasets of PCa were analyzed online (GEO; https://www.ncbi.nlm.nih.gov/geo/geo2r/). 4 normal prostate, 5 localized prostate cancer, and 4 metastatic prostate cancer samples were measured in the array GSE27616. 6 normal prostate, 7 localized prostate cancer, and 6 metastatic prostate cancer samples were measured in the array GSE3325.
To analyze the microarray data, we defined DEGs 1: a comparison of the gene expression between 4 normal prostate and 5 localized prostate cancer samples in GSE27616; DEGs 2: a comparison of the gene expression between 6 normal prostate and 7 localized prostate cancer samples in GSE3325; DEGs 3: a comparison of the gene expression between 5 localized prostate cancer and 4 metastatic prostate cancer samples in GSE27616; DEGs 4: a comparison of the gene expression between 7 localized prostate cancer and 6 metastatic prostate cancer samples in GSE3325. We acquired the overlapped genes between DEGs 1 and DEGs 2 to identify genes involved with tumorigenesis, and defined genes cluster NC represented normal prostate tissue vs. localized cancer tissue. We acquired the overlapped genes between DEGs 3 and DEGs 4 to screen genes that promote tumor metastasis, and defined genes cluster LM represented localized cancer tissue vs. metastatic cancer tissue. DEGs were screened by P value and fold change (FC), restricted by P value < 0.05 and log|FC| ≥ 1. FunRich software (FunRich_3.1.3) was used to identify overlapped DEGs. The upregulated and downregulated genes were measured, respectively.
We proposed the two methods to process the clusters NC and LM: (1) tumorigenesis and metastasis were promoted by the same genes or proteins, the overlapped genes between NC and LM were analyzed to perform Gene Ontology (GO) functional and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis; (2) tumorigenesis and metastasis were contributed by different genes, we would find key genes from clusters NC and LM individually, and NC and LM genes were individually analyzed to perform GO and KEGG pathway analysis and retrieve interacting genes.
The Database for Annotation, Visualization, and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) was used to perform GO functional and KEGG pathway enrichment analyses. P value < 0.05 was set as the cut-off criterion.
Search Tool for the Retrieval of Interacting Genes (STRING) is a biological database (https://string-db.org) for constructing protein-protein interaction (PPI) networks, providing a system-wide view of interactions between each member. DEGs was constructed using STRING database, and an interaction with a combined score > 0.4 was considered statistically significant. Then, we established PPI network using Cytoscape software (Cytoscape_v3.7.2), which visually explores biomolecular interaction networks composed of proteins, genes and other molecules. CytoHubba in Cytoscape software was applied to screen the hub genes ranked by degree. And hub genes represented genes with a large degree and were hypothesized to play a key role in the network.
Disease-free survival (DFS) and overall survival (OS) were analyzed by Gene Expression Profiling Interactive Analysis (GEPIA, http://gepia.cancer-pku.cn/detail/).
Gene expression data were obtained from ONCOMINE website (https://www.oncomine.org/) and UALCAN (http://ualcan.path.uab.edu/analysis.html).
We identified 1881 and 2389 DEGs by analysis of normal prostate tissue vs. localized cancer tissue in GSE27616 and GSE3325, respectively. 3246 and 6331 DEGs by analysis of localized cancer tissue vs. metastatic cancer tissue in GSE27616 and GSE3325, respectively. A comparison of these 4 sets of genes revealed 51 overlapped genes, including 18 upregulated and 33 downregulated DEGs (Figure 1, Table 1). We next analyzed these genes by performing two kinds of functional analysis.
gene symbol | |
upregulated DEGs | TOP2A, MELK, WISP1, CENPF, BIRC5, BUB1, CDK1, NUSAP1, CCNB2, EZH2, DLGAP5, TROAP, KIAA0101, HMMR, CDCA3, NCAPG, CENPA, TMEM132A |
downregulated DEGs | PGM5-AS1, SPOCK3, DST, COL4A6, ACTC1, PGR, SOX5, LDB3, GPD1L, CAV1, CLIC6, C2orf40, SLC8A1, SPON1, SERP2, KIAA1210, SPTLC3, RCAN2, ZBTB20, TENM2, ADAMTS1, CFD, LSAMP, FGFR2, DNAJB5, PCDH9, LINC00844, APCDD1, NDRG2, ZNF853, CRISPLD2, NAALADL1, VSTM4 |
DEGs: differentially expressed genes. |
In the first analysis, the 18 upregulated and 33 downregulated genes that were differentially expressed in both the comparison of normal prostate tissue and localized cancer tissue and the comparison of localized cancer tissue and metastatic cancer tissue were analyzed using the DAVID. GO functional and KEGG pathway enrichment analyses were performed. GO function analysis revealed enrichment of these DEGs in functions related to the proteinaceous extracellular matrix and centrosome. There was an enrichment of genes involved with regulating cell division, protein homodimerization activity, mitotic nuclear division, proteinaceous extracellular matrix, chromatin binding, cell adhesion and apoptotic process. KEGG pathway analysis indicated that the identified DEGs were mainly enriched in progesterone-mediated oocyte maturation, oocyte meiosis and cell cycle. The 20 most enriched classes based on GO function analysis and the 3 most enriched KEGG pathways were listed in Table 2.
Category | Term | Count | % | P value | FDR | |
GO analysis | GOTERM_BP_DIRECT | GO:0051301~cell division | 7 | 13.7254902 | 2.84E-04 | 0.074656255 |
GOTERM_BP_DIRECT | GO:0000086~G2/M transition of mitotic cell cycle | 5 | 9.803921569 | 4.47E-04 | 0.074656255 | |
GOTERM_BP_DIRECT | GO:0007067~mitotic nuclear division | 6 | 11.76470588 | 4.58E-04 | 0.074656255 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 6 | 11.76470588 | 5.55E-04 | 0.069917754 | |
GOTERM_BP_DIRECT | GO:0007062~sister chromatid cohesion | 4 | 7.843137255 | 0.002473069 | 0.302332645 | |
GOTERM_MF_DIRECT | GO:0003682~chromatin binding | 6 | 11.76470588 | 0.003359038 | 0.416520711 | |
GOTERM_CC_DIRECT | GO:0005938~cell cortex | 4 | 7.843137255 | 0.003686069 | 0.231503818 | |
GOTERM_CC_DIRECT | GO:0005876~spindle microtubule | 3 | 5.882352941 | 0.005511996 | 0.231503818 | |
GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 6 | 11.76470588 | 0.006743272 | 0.659491957 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 4 | 7.843137255 | 0.008327156 | 0.460492788 | |
GOTERM_CC_DIRECT | GO:0000775~chromosome, centromeric region | 3 | 5.882352941 | 0.009108061 | 0.286903911 | |
GOTERM_MF_DIRECT | GO:0042803~protein homodimerization activity | 7 | 13.7254902 | 0.011140955 | 0.460492788 | |
GOTERM_BP_DIRECT | GO:0016055~Wnt signaling pathway | 4 | 7.843137255 | 0.012879092 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0070314~G1 to G0 transition | 2 | 3.921568627 | 0.013034542 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0000226~microtubule cytoskeleton organization | 3 | 5.882352941 | 0.014870884 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0008283~cell proliferation | 5 | 9.803921569 | 0.015179728 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0006915~apoptotic process | 6 | 11.76470588 | 0.015821564 | 0.773674476 | |
GOTERM_CC_DIRECT | GO:0045120~pronucleus | 2 | 3.921568627 | 0.017538638 | 0.399420613 | |
GOTERM_CC_DIRECT | GO:0031410~cytoplasmic vesicle | 4 | 7.843137255 | 0.021389738 | 0.399420613 | |
GOTERM_CC_DIRECT | GO:0005813~centrosome | 5 | 9.803921569 | 0.022190034 | 0.399420613 | |
KEGG pathway | KEGG_PATHWAY | hsa04914:Progesterone-mediated oocyte maturation | 4 | 7.843137255 | 7.97E-04 | 0.034252658 |
KEGG_PATHWAY | hsa04114:Oocyte meiosis | 4 | 7.843137255 | 0.001615269 | 0.034728293 | |
KEGG_PATHWAY | hsa04110:Cell cycle | 3 | 5.882352941 | 0.029035349 | 0.416173338 | |
GO: gene ontology; BP: biological process; CC: cellular component; MF: molecular function. |
In the second analysis, we focused on the DEGs identified by the comparison of normal prostate and localized cancer tissues or those identified by the comparison of localized cancer and metastatic cancer tissue samples. Analysis of DEGs from the normal prostate tissue vs. localized cancer tissue comparison should reflect key genes participating in tumorigenesis or PCa development. GO function analysis of these genes found high enrichment of functions related to plasma membrane and extracellular space, heme binding and heparin binding were the main functions of these genes, which participated in oxidation-reduction process, cell adhesion, and response to drug. KEGG pathway analysis indicated enrichment of these genes in protein digestion and absorption, and TGF-beta signaling pathway (Table 3). We next analyzed the DEGs identified by the comparison of localized cancer tissue and metastatic cancer tissue samples, which should include genes related to PCa metastasis. GO function analysis revealed enrichment of these genes in functions related to the extracellular exosome, extracellular region and extracellular space, and analysis of molecular function showed enrichment in protein binding. The most relevant enriched biological processes were cell adhesion, cell division, and cell proliferation and KEGG pathway analysis indicated enrichment of these genes in pathways in cancer, HTLV-I infection, cell cycle and cell adhesion molecules (CAMs) (Table 3).
Prostate cancer development Category | Term | Count | % | P value | FDR | Prostate cancer metastasis Category | Term | Count | % | P value | FDR | |
GO analysis | GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 17 | 4.913294798 | 1.51E-05 | 0.003982498 | GOTERM_CC_DIRECT | GO:0005615~extracellular space | 151 | 11.11929308 | 1.24E-09 | 7.42E-07 |
GOTERM_BP_DIRECT | GO:0042475~odontogenesis of dentin-containing tooth | 7 | 2.023121387 | 3.52E-04 | 0.586071751 | GOTERM_BP_DIRECT | GO:0051301~cell division | 55 | 4.050073638 | 2.98E-08 | 1.30E-04 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 41 | 11.84971098 | 3.99E-04 | 0.052470784 | GOTERM_MF_DIRECT | GO:0005515~protein binding | 706 | 51.98821797 | 3.68E-08 | 3.56E-05 | |
GOTERM_MF_DIRECT | GO:0020037~heme binding | 10 | 2.89017341 | 5.77E-04 | 0.26984829 | GOTERM_MF_DIRECT | GO:0008201~heparin binding | 33 | 2.430044183 | 5.63E-08 | 3.56E-05 | |
GOTERM_BP_DIRECT | GO:0002053~positive regulation of mesenchymal cell proliferation | 5 | 1.445086705 | 9.53E-04 | 0.586071751 | GOTERM_CC_DIRECT | GO:0031012~extracellular matrix | 48 | 3.53460972 | 5.67E-08 | 1.70E-05 | |
GOTERM_BP_DIRECT | GO:0001755~neural crest cell migration | 6 | 1.734104046 | 0.00101455 | 0.586071751 | GOTERM_CC_DIRECT | GO:0009986~cell surface | 70 | 5.154639175 | 4.52E-07 | 9.05E-05 | |
GOTERM_CC_DIRECT | GO:0016323~basolateral plasma membrane | 11 | 3.179190751 | 0.001050682 | 0.092109794 | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 62 | 4.565537555 | 8.88E-07 | 0.001389998 | |
GOTERM_CC_DIRECT | GO:1903561~extracellular vesicle | 6 | 1.734104046 | 0.00156155 | 0.102671884 | GOTERM_BP_DIRECT | GO:0001666~response to hypoxia | 32 | 2.35640648 | 9.54E-07 | 0.001389998 | |
GOTERM_BP_DIRECT | GO:0048701~embryonic cranial skeleton morphogenesis | 5 | 1.445086705 | 0.001874567 | 0.812156124 | GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 253 | 18.63033873 | 1.97E-06 | 2.95E-04 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 93 | 26.87861272 | 0.002175661 | 0.114439759 | GOTERM_BP_DIRECT | GO:0002576~platelet degranulation | 23 | 1.693667158 | 2.00E-06 | 0.002186739 | |
GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 18 | 5.202312139 | 0.002608742 | 0.904189938 | GOTERM_CC_DIRECT | GO:0005576~extracellular region | 158 | 11.634757 | 2.77E-06 | 3.32E-04 | |
GOTERM_CC_DIRECT | GO:0005911~cell-cell junction | 10 | 2.89017341 | 0.002780496 | 0.121878392 | GOTERM_BP_DIRECT | GO:0007062~sister chromatid cohesion | 22 | 1.620029455 | 7.38E-06 | 0.006452155 | |
GOTERM_BP_DIRECT | GO:0007154~cell communication | 5 | 1.445086705 | 0.004002576 | 1 | GOTERM_BP_DIRECT | GO:0007067~mitotic nuclear division | 38 | 2.798232695 | 9.69E-06 | 0.007062396 | |
GOTERM_MF_DIRECT | GO:0045545~syndecan binding | 3 | 0.867052023 | 0.004158161 | 0.648673134 | GOTERM_MF_DIRECT | GO:0005178~integrin binding | 22 | 1.620029455 | 1.05E-05 | 0.004418724 | |
GOTERM_MF_DIRECT | GO:0016174~NAD(P)H oxidase activity | 3 | 0.867052023 | 0.004158161 | 0.648673134 | GOTERM_CC_DIRECT | GO:0030018~Z disc | 23 | 1.693667158 | 1.51E-05 | 0.001511302 | |
GOTERM_BP_DIRECT | GO:0030574~collagen catabolic process | 6 | 1.734104046 | 0.004859514 | 1 | GOTERM_BP_DIRECT | GO:0030198~extracellular matrix organization | 32 | 2.35640648 | 1.56E-05 | 0.0097292 | |
GOTERM_CC_DIRECT | GO:0005938~cell cortex | 8 | 2.312138728 | 0.005103026 | 0.191727963 | GOTERM_BP_DIRECT | GO:0008283~cell proliferation | 49 | 3.608247423 | 1.82E-05 | 0.009935907 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 2.601156069 | 0.006242515 | 0.730374313 | GOTERM_BP_DIRECT | GO:0044344~cellular response to fibroblast growth factor stimulus | 11 | 0.810014728 | 2.21E-05 | 0.010755347 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 13 | 3.757225434 | 0.006583695 | 1 | GOTERM_MF_DIRECT | GO:0042803~protein homodimerization activity | 82 | 6.038291605 | 2.34E-05 | 0.007414289 | |
GOTERM_BP_DIRECT | GO:0055114~oxidation-reduction process | 20 | 5.780346821 | 0.00705709 | 1 | GOTERM_BP_DIRECT | GO:0030336~negative regulation of cell migration | 20 | 1.47275405 | 2.64E-05 | 0.01153048 | |
KEGG pathway | KEGG_PATHWAY | hsa04974:Protein digestion and absorption | 7 | 2.023121387 | 0.004206668 | 0.803473664 | KEGG_PATHWAY | hsa05200:Pathways in cancer | 58 | 4.270986745 | 2.73E-06 | 4.52E-04 |
KEGG_PATHWAY | hsa04350:TGF-beta signaling pathway | 6 | 1.734104046 | 0.01535084 | 1 | KEGG_PATHWAY | hsa05332:Graft-versus-host disease | 13 | 0.957290133 | 3.65E-06 | 4.52E-04 | |
KEGG_PATHWAY | hsa04940:Type I diabetes mellitus | 14 | 1.030927835 | 1.11E-05 | 9.19E-04 | |||||||
KEGG_PATHWAY | hsa04110:Cell cycle | 25 | 1.840942563 | 2.61E-05 | 0.001511671 | |||||||
KEGG_PATHWAY | hsa05166:HTLV-I infection | 40 | 2.9455081 | 3.05E-05 | 0.001511671 | |||||||
KEGG_PATHWAY | hsa04114:Oocyte meiosis | 23 | 1.693667158 | 3.85E-05 | 0.001591416 | |||||||
KEGG_PATHWAY | hsa05416:Viral myocarditis | 15 | 1.104565538 | 9.11E-05 | 0.003228693 | |||||||
KEGG_PATHWAY | hsa05323:Rheumatoid arthritis | 19 | 1.399116348 | 1.26E-04 | 0.003920294 | |||||||
KEGG_PATHWAY | hsa04514:Cell adhesion molecules (CAMs) | 25 | 1.840942563 | 2.43E-04 | 0.006698092 | |||||||
KEGG_PATHWAY | hsa05144:Malaria | 13 | 0.957290133 | 2.97E-04 | 0.007354055 | |||||||
GO: gene ontology; BP: biological process; CC: cellular component; MF: molecular function. |
We used STRING for investigating and integrating interaction between proteins. The PPI network of overlapped DEGs between NC and LM was constructed and data were exported for further analysis by Cytoscape (Figure 2a). And a total of 16 genes were identified as hub genes with degrees ≥ 14, shown in Figure 2b. Also, the top 20 hub genes with the highest degree of connectivity in clusters NC and LM were shown in Figures 2c and 2d, respectively.
We found TOP2A, CCNB2, BUB1, CDK1 and EZH2 were appeared in Figure 2b, Figure 2c and Figure 2d at the same time. The 5 hub genes were all associated with the DFS of PCa patients (Figure 3a-e). KIF20A, CDKN3, PBK and CDCA2 were only appeared in Figure 2c, and the 4 hub genes were also all associated with the DFS of PCa patients (Figure 3f-i). ALB, VEGFA, IL6, PLK1, CCNA2, AURKA, CDC20, KIF11, BUB1B, CHEK1, PTPRC, TPX2, CENPE and CDCA8 were only appeared in Figure 2d, and just ALB, PLK1, CCNA2, AURKA, CDC20, BUB1B, CHEK1, TPX2, CENPE and CDCA8 were associated with the DFS of PCa patients (Figure 3j-s). Among them, we next found an association of PLK1, CCNA2 and CDC20 with overall survival of PCa patients (Figure 3t-v).
Oncomine analysis of prostate cancer vs. normal tissue in Grasso Prostate Statistics showed that the expression levels of TOP2A, CCNB2, BUB1, CDK1 and EZH2 were 2.232-, 1.786-, 2.303-, 1.699-, and 1.986-fold higher in prostate cancer than in normal tissues (P = 8.51E-6, 6.94E-6, 1.14E-5, 0.001, 4.59E-11). The expression levels of KIF20A, CDKN3, PBK and CDCA2 in cluster NC were 1.875-, 1.778-, 2.337-, and 1.889-fold higher in prostate cancer than in normal tissues (P = 5.87E-5, 8.39E-4, 1.86E-6, 7.89E-5). The expression levels of PLK1, CCNA2, CDC20 in cluster LM were 1.326-, 1.231-, and 1.047-fold higher in prostate cancer than in normal tissues (P = 3.91E-4, 0.036, 0.253) (Figure 4, Table 4).
UALCAN is a website that helps analyze, integrate and discover cancer transcriptomic data and deep analyses of TCGA gene expression information. It allows us to offer the differential expression analyses on normal and PCa tissues. It contained 497 PCa tissues and 52 normal prostate samples. As Figure 5 demonstrated, all hub genes significantly overexpressed in PCa tissues than in normal tissues (P < 0.001).
Hub Genes | Fold change (Cancer vs.normal) | P vaule |
TOP2A | 2.232 | 8.51E-6 |
CCNB2 | 1.786 | 6.94E-6 |
BUB1 | 2.303 | 1.14E-5 |
CDK1 | 1.699 | 0.001 |
EZH2 | 1.986 | 4.59E-11 |
KIF20A | 1.875 | 5.87E-5 |
CDKN3 | 1.778 | 8.39E-4 |
PBK | 2.337 | 1.86E-6 |
CDCA2 | 1.889 | 7.89E-5 |
PLK1 | 1.326 | 3.91E-4 |
CCNA2 | 1.231 | 0.036 |
CDC20 | 1.047 | 0.253 |
In this analysis, we defined DEGs for the NC comparison of normal prostate tissue vs. localized cancer tissue and for the LM comparison of localized cancer tissue vs. metastatic cancer tissue in GSE27616 and GSE3325, and considered the identified DEGs contributing to prostate cancer development and contributing to prostate cancer metastasis, respectively. Overlapped genes found in both NC and LM analyses affect both prostate cancer development and metastasis. GO function analysis revealed enrichment of the 51 DEGs overlapped in clusters NC and LM in functions related to the proteinaceous extracellular matrix and centrosome, protein homodimerization activity and chromatin binding were the main functions of these genes, which participated in regulating cell division, mitotic nuclear division, proteinaceous extracellular matrix, cell adhesion and apoptotic process. KEGG pathway analysis indicated that these identified DEGs were mainly enriched in progesterone-mediated oocyte maturation, oocyte meiosis and cell cycle. GO function analysis discovered DEGs in either cluster NC or LM were both enriched in extracellular space, and participated in cell adhesion. Their molecular function and KEGG pathway were different. Heme binding and heparin binding were the main functions of DEGs in cluster NC, and protein binding was the main function of DEGs in cluster LM. KEGG pathway analysis indicated that DEGs in cluster NC were mainly enriched in protein digestion and absorption, and TGF-beta signaling pathway, DEGs in cluster LM were mainly enriched in pathways in cancer, HTLV-I infection, cell cycle and CAMs.
We found that KIF20A, CDKN3, PBK and CDCA2 in cluster NC, expressed higher in prostate cancer than in normal tissues, and were associated with the DFS of prostate cancer patients, maybe associated with prostate cancer development. Although, their expressions were not all elevated in prostate cancer tissue than in normal tissues significantly, PLK1, CCNA2 and CDC20 in cluster LM, were associated with both the DFS and overall survival of prostate cancer patients, may be associated with prostate cancer metastasis. It was interesting that our analysis revealed 5 genes, TOP2A, CCNB2, BUB1, CDK1 and EZH2, overlapped in clusters NC and LM, expressed higher in prostate cancer than in normal tissues, and were associated with the DFS of prostate cancer patients, which may be associated with both prostate cancer development and metastasis.
KIF20A, known as mitotic kinesin-like protein, is a member of the kinesin family protein which is located in the Golgi apparatus and participates in the dynamics of organelle and cell division. Studies ADDIN EN.CITE.DATA [4] have found that KIF20A was abnormally highly expressed in prostate cancer tissues and was associated with adverse prognosis of PCa patients and knockdown of KIF20A could inhibit the proliferation and invasion of prostate cancer cell. Cyclin-dependent kinase inhibitor 3 (CDKN3, also called CDI1 or KAP) is a member of the dual specificity protein phosphatase family, plays an important role in regulating cell division. It has been reported ADDIN EN.CITE.DATA [5] that CDKN3 was over-expressed in PCa and negatively correlated with disease free survival time of PCa. Down-regulation of CDKN3 inhibited proliferation, promoted apoptosis and invasion of PCa cells, and CDKN3 may regulate these biological progresses through associating with cell cycle and DNA replication signal pathways. PDZ-binding kinase (PBK) or T-LAK cell-originated protein kinase (TOPK), is highly homologous to the MAP kinase kinases, particularly MKK3. Physiologically, PBK/TOPK plays a positive regulatory role in proper chromosomal separation and cytokinesis through phosphorylation of various targets. It was found that PBK could be a prognostic biomarker for prostate cancer that would discriminate agammaessive prostate cancer from indolent disease, and was a potential target for the therapeutic intervention of agammaessive prostate cancer in men ADDIN EN.CITE.DATA [6]. CDCA2, also named as Repo-Man (Recruits PP1 onto Mitotic chromatinat anaphase), is a nuclear protein that binds to protein phosphatase 1 γ (PP1γ). It suggested that CDCA2 was responsible for the targeting of PP1 to chromatin during anaphase, leading to the dephosphorylation of H3 and controlled cell proliferation in vitro ADDIN EN.CITE.DATA [7].
Polo-like kinase 1 (PLK1), a serine/threonine kinase that is essential for cell cycle progression, is a novel and major regulator of FOXO1 in the late phases of the cell cycle. Studies have shown that PLK1 dependent phosphorylation of FOXO1 induced its nuclear exclusion and negatively regulated FOXO1′s transcriptional activity in prostate cancer. Blocking the PLK1-dependant phosphorylation of FOXO1 restored the pro-apoptotic function of FOXO1 in PCa. In addition, some studies believed that cotargeting PLK1 and androgen receptor (AR) would be effective in the treatment of paclitaxel-resistant prostate cancer. Yang et al. used weighted gene co-expression network analysis (WGCNA) to analyze hub genes associated with high-stage tumor stage and gleason scores in prostate cancer. They studied CCNA2 and found that it has a significant correlation with biochemical recurrence rate and survival rate of prostate cancer, and verified the role of CCNA2 in prostate cancer cell lines and found that CCNA2 was associated with tumor cell proliferation, invasion, metastasis, and cell cycle. Cell division cycle 20 (CDC20), is a WD40 repeat domain containing E3 ligase that associates with and activates the anaphase-promoting complex (APC). In prostate cancer, Mao et al. ADDIN EN.CITE.DATA [11] demonstrated high expression level of CDC20 associated with higher gleason scores and predicted biochemical recurrence. Li et al. ADDIN EN.CITE.DATA [12] presented the preliminary evidence that CDC20 was significantly involved in mediating chemoresistance to docetaxel partly through inhibiting Wnt/β- catenin signaling.
Metastatic PCa accounts for the majority of PCa specific mortality. However, the ability to distinguish primary PCa with metastatic potential has not been achieved. Studies have shown that primary human PCa with concurrent increased expression of TOP2A and EZH2 have a faster time to biochemical recurrence, were more susceptible to progress to a metastatic disease and thereby resulting in increased PCa specific death ADDIN EN.CITE.DATA [13]. Jin et al. suggested that TROAP and E2F1 were co-regulated by EZH2, TROAP was overexpressed in PCa when compared with the expression in normal tissues, and indicated that TROAP could promote PCa development and progression, at least partially, via a TWIST/c-Myc pathway. Cyclin B2 (CCNB2), a member of the cyclin protein family, has been found to be up-regulated in human cancers. Studies have suggested that detection of serum circulating CCNB2 mRNA may have potential clinical applications in screening and monitoring of metastasis and therapeutic treatments. Other studies suggest that knockdown of circ_CCNB2 was shown to promote PCa radiosensitivity through autophagy repression by miR-30b-5p/KIF18A axis, developing a molecular resistance mechanism of PCa radiotherapy and a feasible strategy to increase radiosensitivity. But the role of CCNB2 in prostate cancer tumorigenesis and metastasis remains unclear. Budding uninhibited by benzimidazoles 1 (BUB1) is a mitotic checkpoint serine/threonine kinase that serves a central role in aligning chromosomes and establishing the mitotic spindle checkpoint. Researches have suggested that the overexpression of BUB1B in PCa cells promoted cell proliferation and migration. Furthermore, high expression levels of BUB1B in PCa were associated with poor clinicopathological features of PCa and predicted poor outcomes of patients with advanced PCa ADDIN EN.CITE.DATA [18]. Cyclin dependent kinase 1 (CDK1, also called CDC2) as an androgen receptor Ser-81 kinase. Researches have indicated that CDK1 can stabilize ARs and that increased CDK1 activity may enhance AR responses to low levels of androgen in androgen-independent PCa. In prostate cancer patients with PSA at diagnosis of < 20 ng /ml, phosphorylation of AR at serine 515 by CDK1 may be an independent prognostic marker. But whether CDK1 plays a role in prostate cancer metastasis is unclear.
Our methods have several limitations that could be improved in future studies. For instance, Zhang et al. ADDIN EN.CITE.DATA [21] developed a time-course RNA-seq data-driven computational method to study the network mechanisms underlying cancer drug resistance, we also can use the method to study whether the identified hub genes are associated with the targeted therapy response and prognosis of PCa patients. Zhang et al. presented a promising single-cell RNA-seq transcriptome-based multilayer network approach to elucidate the interactions between tumor cell and tumor-associated microenvironment and to identify prognostic and predictive signatures of cancer patients, we can combine single-cell RNA-seq data with clinical gene expression data to develop a computational pipeline for identifying the prognostic and predictive signature that connects cancer cells and microenvironmental cells. Then the single-cell RNA-seq transcriptome-based multilayer network biomarker may predict survival outcome and therapeutic response of PCa patients.
The present study analyzed the gene expression profiles of localized and metastatic prostate cancer tissue using bioinformatics analysis. It was identified that DEGs, may serve roles in development and metastasis of prostate cancer. These genes may become the novel potential biomarkers and therapeutic targets for patients with prostate cancer, and distinguish metastatic potential patients with indolent prostate cancer. However, further research is required to confirm whether these genes play a developmental or metastatic role in prostate cancer, or both.
This work is supported by the Science and Technology Development Guidance Plan (Medical and Health) Project of Wuxi (CZ2020003).
The authors declare there is no conflict of interest.
[1] |
R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, Cancer Statistics, 2021, CA. Cancer J. Clin., 71 (2021), 7-33. doi: 10.3322/caac.21654
![]() |
[2] |
J. A. Hempelmann, C. M. Lockwood, E. Q. Konnick, M. T. Schweizer, E. S. Antonarakis, T. L. Lotan, et al., Microsatellite instability in prostate cancer by PCR or next-generation sequencing, J. Immunother. Cancer, 6 (2018), 29. doi: 10.1186/s40425-018-0341-y
![]() |
[3] |
L. Foj, X. Filella, Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis, Pathol. Oncol. Res., 25 (2019), 1445-1456. doi: 10.1007/s12253-018-0508-3
![]() |
[4] | Z. Zhang, C. Chai, T. Shen, X. Li, J. Ji, C. Li, et al., Aberrant KIF20A expression is associated with adverse clinical outcome and promotes tumor progression in Prostate Cancer, Dis. Markers, (2019), 4782730. |
[5] |
C. Yu, H. Cao, X. He, P. Sun, Y. Feng, L. Chen, et al., Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling, Biomed. Pharmacother., 96 (2017), 1109-1118. doi: 10.1016/j.biopha.2017.11.112
![]() |
[6] |
J. D. Brown-Clay, D. N. Shenoy, O. Timofeeva, B. V. Kallakury, A. K. Nandi, P. P. Banerjee, PBK/TOPK enhances aggressive phenotype in prostate cancer via beta-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion, Oncotarget, 6 (2015), 15594-15609. doi: 10.18632/oncotarget.3709
![]() |
[7] |
Y. Zhang, Y. Cheng, Z. Zhang, Z. Bai, H. Jin, X. Guo, et al., CDCA2 inhibits apoptosis and promotes cell proliferation in Prostate Cancer and is directly regulated by HIF-1alpha pathway, Front. Oncol., 10 (2020), 725. doi: 10.3389/fonc.2020.00725
![]() |
[8] |
L. Gheghiani, S. Shang, Z. Fu, Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer, Sci. Rep., 10 (2020), 12327. doi: 10.1038/s41598-020-69338-8
![]() |
[9] | S. B. Shin, S. U. Woo, H. Yim, Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer, Ther. Adv. Med. Oncol., 11 (2019), 1758835919846375. |
[10] |
R. Yang, Y. Du, L. Wang, Z. Chen, X. Liu, Weighted gene co-expression network analysis identifies CCNA2 as a treatment target of prostate cancer through inhibiting cell cycle, J. Cancer, 11 (2020), 1203-1211. doi: 10.7150/jca.38173
![]() |
[11] |
Y. Mao, K. Li, L. Lu, J. Si-Tu, M. Lu, X. Gao, Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy, Cancer Biomark., 16 (2016), 351-358. doi: 10.3233/CBM-160573
![]() |
[12] |
K. Li, Y. Mao, L. Lu, C. Hu, D. Wang, J. Si-Tu, et al., Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel, Int. J. Oncol., 49 (2016), 1679-1685. doi: 10.3892/ijo.2016.3671
![]() |
[13] |
D. P. Labbe, C. J. Sweeney, M. Brown, P. Galbo, S. Rosario, K. M. Wadosky, et al., TOP2A and EZH2 provide early detection of an aggressive Prostate Cancer subgroup, Clin. Cancer Res., 23 (2017), 7072-7083. doi: 10.1158/1078-0432.CCR-17-0413
![]() |
[14] |
L. Jin, Y. Zhou, G. Chen, G. Dai, K. Fu, D. Yang, et al., EZH2-TROAP pathway promotes Prostate Cancer progression via TWIST signals, Front. Oncol., 10 (2021), 592239. doi: 10.3389/fonc.2020.592239
![]() |
[15] | M. L. Mo, Z. Chen, J. Li, H. L. Li, Q. Sheng, H. Y. Ma, et al., Use of serum circulating CCNB2 in cancer surveillance, Int. J. Biol. Markers, 25 (2010), 30B1A552-6F86-4064-888D-90FEC7A5BB29. |
[16] | F. Cai, J. Li, J. Zhang, S. Huang, Knockdown of Circ_CCNB2 sensitizes Prostate Cancer to radiation through repressing autophagy by the miR-30b-5p/KIF18A axis, Cancer Biother. Radiopharm., (2020), Online ahead of print. |
[17] | L. J. Zhu, Y. Pan, X. Y. Chen, P. F. Hou, BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation, Oncol. Lett., 19 (2020), 3506-3512. |
[18] | X. Fu, G. Chen, Z. D. Cai, C. Wang, Z. Z. Liu, Z. Y. Lin, et al., Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer, Onco. Targets Ther., 9 (2016), 2211-2220. |
[19] |
S. Chen, Y. Xu, X. Yuan, G. J. Bubley, S. P. Balk, Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1, Proc. Natl. Acad. Sci. U.S.A., 103 (2006), 15969-15974. doi: 10.1073/pnas.0604193103
![]() |
[20] |
J. M. Willder, S. J. Heng, P. McCall, C. E. Adams, C. Tannahill, G. Fyffe, et al., Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients, Br. J. Cancer, 108 (2013), 139-148. doi: 10.1038/bjc.2012.480
![]() |
[21] |
J. Zhang, W. Zhu, Q. Wang, J. Gu, L. F. Huang, X. Sun, Differential regulatory network-based quantification and prioritization of key genes underlying cancer drug resistance based on time-course RNA-seq data, PLoS. Comput. Biol., 15 (2019), e1007435. doi: 10.1371/journal.pcbi.1007435
![]() |
[22] |
J. Zhang, M. Guan, Q. Wang, J. Zhang, T. Zhou, X. Sun, Single-cell transcriptome-based multilayer network biomarker for predicting prognosis and therapeutic response of gliomas, Brief. Bioinform., 21 (2020), 1080-1097. doi: 10.1093/bib/bbz040
![]() |
1. | Xin Deng, Jia Ma, Wenyang Zhou, Yifeng Yuan, Baosheng Wang, Xiangpeng Meng, GID2 interacts with CDKN3 and regulates pancreatic cancer growth and apoptosis, 2023, 00236837, 100122, 10.1016/j.labinv.2023.100122 | |
2. | Peng Gu, Minhao Zhang, Jin Zhu, Xiaoliang He, Dongrong Yang, Suppression of CDCA3 inhibits prostate cancer progression via NF‑κB/cyclin D1 signaling inactivation and p21 accumulation, 2021, 47, 1021-335X, 10.3892/or.2021.8253 | |
3. | Yingjuan Liang, Jinpeng Wang, Xinyu Li, Shuang Wu, Chaoqian Jiang, Yue Wang, Xuechun Li, Zhong-Hua Liu, Yanshuang Mu, Exploring differentially expressed genes related to metabolism by RNA-Seq in porcine embryonic fibroblast after insulin treatment, 2022, 23, 1229-845X, 10.4142/jvs.22088 | |
4. | Manny D. Bacolod, Francis Barany, A Unified Transcriptional, Pharmacogenomic, and Gene Dependency Approach to Decipher the Biology, Diagnostic Markers, and Therapeutic Targets Associated with Prostate Cancer Metastasis, 2021, 13, 2072-6694, 5158, 10.3390/cancers13205158 | |
5. | Peng Gu, Dongrong Yang, Jin Zhu, Minhao Zhang, Xiaoliang He, Bioinformatics analysis of the clinical relevance of CDCA gene family in prostate cancer, 2022, 101, 0025-7974, e28788, 10.1097/MD.0000000000028788 | |
6. | Xin Jin, Zhen-qing Sun, Gui-liang Zhou, Guo-jun Li, Shi-feng Deng, Zhongjie Shi, The Higher Expression of CDCA2 Associated with Poor Prognosis in Glioma, 2022, 2022, 1875-8630, 1, 10.1155/2022/2184867 | |
7. | Katie Joanna Miller, Isla Henry, Zoe Maylin, Christopher Smith, Einthavy Arunachalam, Hardev Pandha, Mohammad Asim, A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer, 2023, 13, 2234-943X, 10.3389/fonc.2023.1129140 | |
8. | Zainab A. H. Alebady, Mahsa Azizyan, Sirintra Nakjang, Emma Lishman-Walker, Dhuha Al-Kharaif, Scott Walker, Hui Xian Choo, Rebecca Garnham, Emma Scott, Katya L. Johnson, Craig N. Robson, Kelly Coffey, CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration-Resistant Prostate Cancer, 2023, 15, 2072-6694, 3597, 10.3390/cancers15143597 | |
9. | Chuanlong Zhang, Qian Shen, Mengqi Gao, Junchen Li, Bo Pang, The role of Cyclin Dependent Kinase Inhibitor 3 (CDKN3) in promoting human tumors: Literature review and pan-cancer analysis, 2024, 10, 24058440, e26061, 10.1016/j.heliyon.2024.e26061 | |
10. | Xinyi Lin, Zijian Zou, Jingqin Zhong, Tong Wang, Wenjie Ma, Tu Hu, Wei Sun, Yu Xu, Alexander M.M. Eggermont, Yong Chen, The Role of CDCA2 in tumor genesis, prognosis and future treatments, 2024, 211, 09598049, 114308, 10.1016/j.ejca.2024.114308 | |
11. | Peng Gu, Minhao Zhang, Xinhua Chen, Jie Du, Lu Chen, Xiaoliang He, Meilin Li, Prognostic value of cell division cycle-associated protein-3 in prostate cancer, 2023, 102, 0025-7974, e34655, 10.1097/MD.0000000000034655 | |
12. | Peiliang Zou, Shenghai Li, Qixiong He, Chixing Zheng, Berberine inhibits prostate cancer progression by inducing ferroptosis: evidence from network pharmacology, 2025, 0959-4973, 10.1097/CAD.0000000000001691 |
gene symbol | |
upregulated DEGs | TOP2A, MELK, WISP1, CENPF, BIRC5, BUB1, CDK1, NUSAP1, CCNB2, EZH2, DLGAP5, TROAP, KIAA0101, HMMR, CDCA3, NCAPG, CENPA, TMEM132A |
downregulated DEGs | PGM5-AS1, SPOCK3, DST, COL4A6, ACTC1, PGR, SOX5, LDB3, GPD1L, CAV1, CLIC6, C2orf40, SLC8A1, SPON1, SERP2, KIAA1210, SPTLC3, RCAN2, ZBTB20, TENM2, ADAMTS1, CFD, LSAMP, FGFR2, DNAJB5, PCDH9, LINC00844, APCDD1, NDRG2, ZNF853, CRISPLD2, NAALADL1, VSTM4 |
DEGs: differentially expressed genes. |
Category | Term | Count | % | P value | FDR | |
GO analysis | GOTERM_BP_DIRECT | GO:0051301~cell division | 7 | 13.7254902 | 2.84E-04 | 0.074656255 |
GOTERM_BP_DIRECT | GO:0000086~G2/M transition of mitotic cell cycle | 5 | 9.803921569 | 4.47E-04 | 0.074656255 | |
GOTERM_BP_DIRECT | GO:0007067~mitotic nuclear division | 6 | 11.76470588 | 4.58E-04 | 0.074656255 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 6 | 11.76470588 | 5.55E-04 | 0.069917754 | |
GOTERM_BP_DIRECT | GO:0007062~sister chromatid cohesion | 4 | 7.843137255 | 0.002473069 | 0.302332645 | |
GOTERM_MF_DIRECT | GO:0003682~chromatin binding | 6 | 11.76470588 | 0.003359038 | 0.416520711 | |
GOTERM_CC_DIRECT | GO:0005938~cell cortex | 4 | 7.843137255 | 0.003686069 | 0.231503818 | |
GOTERM_CC_DIRECT | GO:0005876~spindle microtubule | 3 | 5.882352941 | 0.005511996 | 0.231503818 | |
GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 6 | 11.76470588 | 0.006743272 | 0.659491957 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 4 | 7.843137255 | 0.008327156 | 0.460492788 | |
GOTERM_CC_DIRECT | GO:0000775~chromosome, centromeric region | 3 | 5.882352941 | 0.009108061 | 0.286903911 | |
GOTERM_MF_DIRECT | GO:0042803~protein homodimerization activity | 7 | 13.7254902 | 0.011140955 | 0.460492788 | |
GOTERM_BP_DIRECT | GO:0016055~Wnt signaling pathway | 4 | 7.843137255 | 0.012879092 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0070314~G1 to G0 transition | 2 | 3.921568627 | 0.013034542 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0000226~microtubule cytoskeleton organization | 3 | 5.882352941 | 0.014870884 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0008283~cell proliferation | 5 | 9.803921569 | 0.015179728 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0006915~apoptotic process | 6 | 11.76470588 | 0.015821564 | 0.773674476 | |
GOTERM_CC_DIRECT | GO:0045120~pronucleus | 2 | 3.921568627 | 0.017538638 | 0.399420613 | |
GOTERM_CC_DIRECT | GO:0031410~cytoplasmic vesicle | 4 | 7.843137255 | 0.021389738 | 0.399420613 | |
GOTERM_CC_DIRECT | GO:0005813~centrosome | 5 | 9.803921569 | 0.022190034 | 0.399420613 | |
KEGG pathway | KEGG_PATHWAY | hsa04914:Progesterone-mediated oocyte maturation | 4 | 7.843137255 | 7.97E-04 | 0.034252658 |
KEGG_PATHWAY | hsa04114:Oocyte meiosis | 4 | 7.843137255 | 0.001615269 | 0.034728293 | |
KEGG_PATHWAY | hsa04110:Cell cycle | 3 | 5.882352941 | 0.029035349 | 0.416173338 | |
GO: gene ontology; BP: biological process; CC: cellular component; MF: molecular function. |
Prostate cancer development Category | Term | Count | % | P value | FDR | Prostate cancer metastasis Category | Term | Count | % | P value | FDR | |
GO analysis | GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 17 | 4.913294798 | 1.51E-05 | 0.003982498 | GOTERM_CC_DIRECT | GO:0005615~extracellular space | 151 | 11.11929308 | 1.24E-09 | 7.42E-07 |
GOTERM_BP_DIRECT | GO:0042475~odontogenesis of dentin-containing tooth | 7 | 2.023121387 | 3.52E-04 | 0.586071751 | GOTERM_BP_DIRECT | GO:0051301~cell division | 55 | 4.050073638 | 2.98E-08 | 1.30E-04 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 41 | 11.84971098 | 3.99E-04 | 0.052470784 | GOTERM_MF_DIRECT | GO:0005515~protein binding | 706 | 51.98821797 | 3.68E-08 | 3.56E-05 | |
GOTERM_MF_DIRECT | GO:0020037~heme binding | 10 | 2.89017341 | 5.77E-04 | 0.26984829 | GOTERM_MF_DIRECT | GO:0008201~heparin binding | 33 | 2.430044183 | 5.63E-08 | 3.56E-05 | |
GOTERM_BP_DIRECT | GO:0002053~positive regulation of mesenchymal cell proliferation | 5 | 1.445086705 | 9.53E-04 | 0.586071751 | GOTERM_CC_DIRECT | GO:0031012~extracellular matrix | 48 | 3.53460972 | 5.67E-08 | 1.70E-05 | |
GOTERM_BP_DIRECT | GO:0001755~neural crest cell migration | 6 | 1.734104046 | 0.00101455 | 0.586071751 | GOTERM_CC_DIRECT | GO:0009986~cell surface | 70 | 5.154639175 | 4.52E-07 | 9.05E-05 | |
GOTERM_CC_DIRECT | GO:0016323~basolateral plasma membrane | 11 | 3.179190751 | 0.001050682 | 0.092109794 | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 62 | 4.565537555 | 8.88E-07 | 0.001389998 | |
GOTERM_CC_DIRECT | GO:1903561~extracellular vesicle | 6 | 1.734104046 | 0.00156155 | 0.102671884 | GOTERM_BP_DIRECT | GO:0001666~response to hypoxia | 32 | 2.35640648 | 9.54E-07 | 0.001389998 | |
GOTERM_BP_DIRECT | GO:0048701~embryonic cranial skeleton morphogenesis | 5 | 1.445086705 | 0.001874567 | 0.812156124 | GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 253 | 18.63033873 | 1.97E-06 | 2.95E-04 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 93 | 26.87861272 | 0.002175661 | 0.114439759 | GOTERM_BP_DIRECT | GO:0002576~platelet degranulation | 23 | 1.693667158 | 2.00E-06 | 0.002186739 | |
GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 18 | 5.202312139 | 0.002608742 | 0.904189938 | GOTERM_CC_DIRECT | GO:0005576~extracellular region | 158 | 11.634757 | 2.77E-06 | 3.32E-04 | |
GOTERM_CC_DIRECT | GO:0005911~cell-cell junction | 10 | 2.89017341 | 0.002780496 | 0.121878392 | GOTERM_BP_DIRECT | GO:0007062~sister chromatid cohesion | 22 | 1.620029455 | 7.38E-06 | 0.006452155 | |
GOTERM_BP_DIRECT | GO:0007154~cell communication | 5 | 1.445086705 | 0.004002576 | 1 | GOTERM_BP_DIRECT | GO:0007067~mitotic nuclear division | 38 | 2.798232695 | 9.69E-06 | 0.007062396 | |
GOTERM_MF_DIRECT | GO:0045545~syndecan binding | 3 | 0.867052023 | 0.004158161 | 0.648673134 | GOTERM_MF_DIRECT | GO:0005178~integrin binding | 22 | 1.620029455 | 1.05E-05 | 0.004418724 | |
GOTERM_MF_DIRECT | GO:0016174~NAD(P)H oxidase activity | 3 | 0.867052023 | 0.004158161 | 0.648673134 | GOTERM_CC_DIRECT | GO:0030018~Z disc | 23 | 1.693667158 | 1.51E-05 | 0.001511302 | |
GOTERM_BP_DIRECT | GO:0030574~collagen catabolic process | 6 | 1.734104046 | 0.004859514 | 1 | GOTERM_BP_DIRECT | GO:0030198~extracellular matrix organization | 32 | 2.35640648 | 1.56E-05 | 0.0097292 | |
GOTERM_CC_DIRECT | GO:0005938~cell cortex | 8 | 2.312138728 | 0.005103026 | 0.191727963 | GOTERM_BP_DIRECT | GO:0008283~cell proliferation | 49 | 3.608247423 | 1.82E-05 | 0.009935907 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 2.601156069 | 0.006242515 | 0.730374313 | GOTERM_BP_DIRECT | GO:0044344~cellular response to fibroblast growth factor stimulus | 11 | 0.810014728 | 2.21E-05 | 0.010755347 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 13 | 3.757225434 | 0.006583695 | 1 | GOTERM_MF_DIRECT | GO:0042803~protein homodimerization activity | 82 | 6.038291605 | 2.34E-05 | 0.007414289 | |
GOTERM_BP_DIRECT | GO:0055114~oxidation-reduction process | 20 | 5.780346821 | 0.00705709 | 1 | GOTERM_BP_DIRECT | GO:0030336~negative regulation of cell migration | 20 | 1.47275405 | 2.64E-05 | 0.01153048 | |
KEGG pathway | KEGG_PATHWAY | hsa04974:Protein digestion and absorption | 7 | 2.023121387 | 0.004206668 | 0.803473664 | KEGG_PATHWAY | hsa05200:Pathways in cancer | 58 | 4.270986745 | 2.73E-06 | 4.52E-04 |
KEGG_PATHWAY | hsa04350:TGF-beta signaling pathway | 6 | 1.734104046 | 0.01535084 | 1 | KEGG_PATHWAY | hsa05332:Graft-versus-host disease | 13 | 0.957290133 | 3.65E-06 | 4.52E-04 | |
KEGG_PATHWAY | hsa04940:Type I diabetes mellitus | 14 | 1.030927835 | 1.11E-05 | 9.19E-04 | |||||||
KEGG_PATHWAY | hsa04110:Cell cycle | 25 | 1.840942563 | 2.61E-05 | 0.001511671 | |||||||
KEGG_PATHWAY | hsa05166:HTLV-I infection | 40 | 2.9455081 | 3.05E-05 | 0.001511671 | |||||||
KEGG_PATHWAY | hsa04114:Oocyte meiosis | 23 | 1.693667158 | 3.85E-05 | 0.001591416 | |||||||
KEGG_PATHWAY | hsa05416:Viral myocarditis | 15 | 1.104565538 | 9.11E-05 | 0.003228693 | |||||||
KEGG_PATHWAY | hsa05323:Rheumatoid arthritis | 19 | 1.399116348 | 1.26E-04 | 0.003920294 | |||||||
KEGG_PATHWAY | hsa04514:Cell adhesion molecules (CAMs) | 25 | 1.840942563 | 2.43E-04 | 0.006698092 | |||||||
KEGG_PATHWAY | hsa05144:Malaria | 13 | 0.957290133 | 2.97E-04 | 0.007354055 | |||||||
GO: gene ontology; BP: biological process; CC: cellular component; MF: molecular function. |
Hub Genes | Fold change (Cancer vs.normal) | P vaule |
TOP2A | 2.232 | 8.51E-6 |
CCNB2 | 1.786 | 6.94E-6 |
BUB1 | 2.303 | 1.14E-5 |
CDK1 | 1.699 | 0.001 |
EZH2 | 1.986 | 4.59E-11 |
KIF20A | 1.875 | 5.87E-5 |
CDKN3 | 1.778 | 8.39E-4 |
PBK | 2.337 | 1.86E-6 |
CDCA2 | 1.889 | 7.89E-5 |
PLK1 | 1.326 | 3.91E-4 |
CCNA2 | 1.231 | 0.036 |
CDC20 | 1.047 | 0.253 |
gene symbol | |
upregulated DEGs | TOP2A, MELK, WISP1, CENPF, BIRC5, BUB1, CDK1, NUSAP1, CCNB2, EZH2, DLGAP5, TROAP, KIAA0101, HMMR, CDCA3, NCAPG, CENPA, TMEM132A |
downregulated DEGs | PGM5-AS1, SPOCK3, DST, COL4A6, ACTC1, PGR, SOX5, LDB3, GPD1L, CAV1, CLIC6, C2orf40, SLC8A1, SPON1, SERP2, KIAA1210, SPTLC3, RCAN2, ZBTB20, TENM2, ADAMTS1, CFD, LSAMP, FGFR2, DNAJB5, PCDH9, LINC00844, APCDD1, NDRG2, ZNF853, CRISPLD2, NAALADL1, VSTM4 |
DEGs: differentially expressed genes. |
Category | Term | Count | % | P value | FDR | |
GO analysis | GOTERM_BP_DIRECT | GO:0051301~cell division | 7 | 13.7254902 | 2.84E-04 | 0.074656255 |
GOTERM_BP_DIRECT | GO:0000086~G2/M transition of mitotic cell cycle | 5 | 9.803921569 | 4.47E-04 | 0.074656255 | |
GOTERM_BP_DIRECT | GO:0007067~mitotic nuclear division | 6 | 11.76470588 | 4.58E-04 | 0.074656255 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 6 | 11.76470588 | 5.55E-04 | 0.069917754 | |
GOTERM_BP_DIRECT | GO:0007062~sister chromatid cohesion | 4 | 7.843137255 | 0.002473069 | 0.302332645 | |
GOTERM_MF_DIRECT | GO:0003682~chromatin binding | 6 | 11.76470588 | 0.003359038 | 0.416520711 | |
GOTERM_CC_DIRECT | GO:0005938~cell cortex | 4 | 7.843137255 | 0.003686069 | 0.231503818 | |
GOTERM_CC_DIRECT | GO:0005876~spindle microtubule | 3 | 5.882352941 | 0.005511996 | 0.231503818 | |
GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 6 | 11.76470588 | 0.006743272 | 0.659491957 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 4 | 7.843137255 | 0.008327156 | 0.460492788 | |
GOTERM_CC_DIRECT | GO:0000775~chromosome, centromeric region | 3 | 5.882352941 | 0.009108061 | 0.286903911 | |
GOTERM_MF_DIRECT | GO:0042803~protein homodimerization activity | 7 | 13.7254902 | 0.011140955 | 0.460492788 | |
GOTERM_BP_DIRECT | GO:0016055~Wnt signaling pathway | 4 | 7.843137255 | 0.012879092 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0070314~G1 to G0 transition | 2 | 3.921568627 | 0.013034542 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0000226~microtubule cytoskeleton organization | 3 | 5.882352941 | 0.014870884 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0008283~cell proliferation | 5 | 9.803921569 | 0.015179728 | 0.773674476 | |
GOTERM_BP_DIRECT | GO:0006915~apoptotic process | 6 | 11.76470588 | 0.015821564 | 0.773674476 | |
GOTERM_CC_DIRECT | GO:0045120~pronucleus | 2 | 3.921568627 | 0.017538638 | 0.399420613 | |
GOTERM_CC_DIRECT | GO:0031410~cytoplasmic vesicle | 4 | 7.843137255 | 0.021389738 | 0.399420613 | |
GOTERM_CC_DIRECT | GO:0005813~centrosome | 5 | 9.803921569 | 0.022190034 | 0.399420613 | |
KEGG pathway | KEGG_PATHWAY | hsa04914:Progesterone-mediated oocyte maturation | 4 | 7.843137255 | 7.97E-04 | 0.034252658 |
KEGG_PATHWAY | hsa04114:Oocyte meiosis | 4 | 7.843137255 | 0.001615269 | 0.034728293 | |
KEGG_PATHWAY | hsa04110:Cell cycle | 3 | 5.882352941 | 0.029035349 | 0.416173338 | |
GO: gene ontology; BP: biological process; CC: cellular component; MF: molecular function. |
Prostate cancer development Category | Term | Count | % | P value | FDR | Prostate cancer metastasis Category | Term | Count | % | P value | FDR | |
GO analysis | GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 17 | 4.913294798 | 1.51E-05 | 0.003982498 | GOTERM_CC_DIRECT | GO:0005615~extracellular space | 151 | 11.11929308 | 1.24E-09 | 7.42E-07 |
GOTERM_BP_DIRECT | GO:0042475~odontogenesis of dentin-containing tooth | 7 | 2.023121387 | 3.52E-04 | 0.586071751 | GOTERM_BP_DIRECT | GO:0051301~cell division | 55 | 4.050073638 | 2.98E-08 | 1.30E-04 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 41 | 11.84971098 | 3.99E-04 | 0.052470784 | GOTERM_MF_DIRECT | GO:0005515~protein binding | 706 | 51.98821797 | 3.68E-08 | 3.56E-05 | |
GOTERM_MF_DIRECT | GO:0020037~heme binding | 10 | 2.89017341 | 5.77E-04 | 0.26984829 | GOTERM_MF_DIRECT | GO:0008201~heparin binding | 33 | 2.430044183 | 5.63E-08 | 3.56E-05 | |
GOTERM_BP_DIRECT | GO:0002053~positive regulation of mesenchymal cell proliferation | 5 | 1.445086705 | 9.53E-04 | 0.586071751 | GOTERM_CC_DIRECT | GO:0031012~extracellular matrix | 48 | 3.53460972 | 5.67E-08 | 1.70E-05 | |
GOTERM_BP_DIRECT | GO:0001755~neural crest cell migration | 6 | 1.734104046 | 0.00101455 | 0.586071751 | GOTERM_CC_DIRECT | GO:0009986~cell surface | 70 | 5.154639175 | 4.52E-07 | 9.05E-05 | |
GOTERM_CC_DIRECT | GO:0016323~basolateral plasma membrane | 11 | 3.179190751 | 0.001050682 | 0.092109794 | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 62 | 4.565537555 | 8.88E-07 | 0.001389998 | |
GOTERM_CC_DIRECT | GO:1903561~extracellular vesicle | 6 | 1.734104046 | 0.00156155 | 0.102671884 | GOTERM_BP_DIRECT | GO:0001666~response to hypoxia | 32 | 2.35640648 | 9.54E-07 | 0.001389998 | |
GOTERM_BP_DIRECT | GO:0048701~embryonic cranial skeleton morphogenesis | 5 | 1.445086705 | 0.001874567 | 0.812156124 | GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 253 | 18.63033873 | 1.97E-06 | 2.95E-04 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 93 | 26.87861272 | 0.002175661 | 0.114439759 | GOTERM_BP_DIRECT | GO:0002576~platelet degranulation | 23 | 1.693667158 | 2.00E-06 | 0.002186739 | |
GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 18 | 5.202312139 | 0.002608742 | 0.904189938 | GOTERM_CC_DIRECT | GO:0005576~extracellular region | 158 | 11.634757 | 2.77E-06 | 3.32E-04 | |
GOTERM_CC_DIRECT | GO:0005911~cell-cell junction | 10 | 2.89017341 | 0.002780496 | 0.121878392 | GOTERM_BP_DIRECT | GO:0007062~sister chromatid cohesion | 22 | 1.620029455 | 7.38E-06 | 0.006452155 | |
GOTERM_BP_DIRECT | GO:0007154~cell communication | 5 | 1.445086705 | 0.004002576 | 1 | GOTERM_BP_DIRECT | GO:0007067~mitotic nuclear division | 38 | 2.798232695 | 9.69E-06 | 0.007062396 | |
GOTERM_MF_DIRECT | GO:0045545~syndecan binding | 3 | 0.867052023 | 0.004158161 | 0.648673134 | GOTERM_MF_DIRECT | GO:0005178~integrin binding | 22 | 1.620029455 | 1.05E-05 | 0.004418724 | |
GOTERM_MF_DIRECT | GO:0016174~NAD(P)H oxidase activity | 3 | 0.867052023 | 0.004158161 | 0.648673134 | GOTERM_CC_DIRECT | GO:0030018~Z disc | 23 | 1.693667158 | 1.51E-05 | 0.001511302 | |
GOTERM_BP_DIRECT | GO:0030574~collagen catabolic process | 6 | 1.734104046 | 0.004859514 | 1 | GOTERM_BP_DIRECT | GO:0030198~extracellular matrix organization | 32 | 2.35640648 | 1.56E-05 | 0.0097292 | |
GOTERM_CC_DIRECT | GO:0005938~cell cortex | 8 | 2.312138728 | 0.005103026 | 0.191727963 | GOTERM_BP_DIRECT | GO:0008283~cell proliferation | 49 | 3.608247423 | 1.82E-05 | 0.009935907 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 2.601156069 | 0.006242515 | 0.730374313 | GOTERM_BP_DIRECT | GO:0044344~cellular response to fibroblast growth factor stimulus | 11 | 0.810014728 | 2.21E-05 | 0.010755347 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 13 | 3.757225434 | 0.006583695 | 1 | GOTERM_MF_DIRECT | GO:0042803~protein homodimerization activity | 82 | 6.038291605 | 2.34E-05 | 0.007414289 | |
GOTERM_BP_DIRECT | GO:0055114~oxidation-reduction process | 20 | 5.780346821 | 0.00705709 | 1 | GOTERM_BP_DIRECT | GO:0030336~negative regulation of cell migration | 20 | 1.47275405 | 2.64E-05 | 0.01153048 | |
KEGG pathway | KEGG_PATHWAY | hsa04974:Protein digestion and absorption | 7 | 2.023121387 | 0.004206668 | 0.803473664 | KEGG_PATHWAY | hsa05200:Pathways in cancer | 58 | 4.270986745 | 2.73E-06 | 4.52E-04 |
KEGG_PATHWAY | hsa04350:TGF-beta signaling pathway | 6 | 1.734104046 | 0.01535084 | 1 | KEGG_PATHWAY | hsa05332:Graft-versus-host disease | 13 | 0.957290133 | 3.65E-06 | 4.52E-04 | |
KEGG_PATHWAY | hsa04940:Type I diabetes mellitus | 14 | 1.030927835 | 1.11E-05 | 9.19E-04 | |||||||
KEGG_PATHWAY | hsa04110:Cell cycle | 25 | 1.840942563 | 2.61E-05 | 0.001511671 | |||||||
KEGG_PATHWAY | hsa05166:HTLV-I infection | 40 | 2.9455081 | 3.05E-05 | 0.001511671 | |||||||
KEGG_PATHWAY | hsa04114:Oocyte meiosis | 23 | 1.693667158 | 3.85E-05 | 0.001591416 | |||||||
KEGG_PATHWAY | hsa05416:Viral myocarditis | 15 | 1.104565538 | 9.11E-05 | 0.003228693 | |||||||
KEGG_PATHWAY | hsa05323:Rheumatoid arthritis | 19 | 1.399116348 | 1.26E-04 | 0.003920294 | |||||||
KEGG_PATHWAY | hsa04514:Cell adhesion molecules (CAMs) | 25 | 1.840942563 | 2.43E-04 | 0.006698092 | |||||||
KEGG_PATHWAY | hsa05144:Malaria | 13 | 0.957290133 | 2.97E-04 | 0.007354055 | |||||||
GO: gene ontology; BP: biological process; CC: cellular component; MF: molecular function. |
Hub Genes | Fold change (Cancer vs.normal) | P vaule |
TOP2A | 2.232 | 8.51E-6 |
CCNB2 | 1.786 | 6.94E-6 |
BUB1 | 2.303 | 1.14E-5 |
CDK1 | 1.699 | 0.001 |
EZH2 | 1.986 | 4.59E-11 |
KIF20A | 1.875 | 5.87E-5 |
CDKN3 | 1.778 | 8.39E-4 |
PBK | 2.337 | 1.86E-6 |
CDCA2 | 1.889 | 7.89E-5 |
PLK1 | 1.326 | 3.91E-4 |
CCNA2 | 1.231 | 0.036 |
CDC20 | 1.047 | 0.253 |